Sentence examples for binding we developed a from inspiring English sources

To address this issue of combinatorial binding, we developed a new tool called combinatorial GSCA (C-GSCA), and then applied this new tool to our hematopoietic ChIP-Seq compendium.

To confirm that the distal region of CD4c was important to support PLSCR1 binding, we developed an ELISA to recapitulate the CD4-PLSCR1 interaction in vitro.

To overcome this hurdle and gain insight into rhomboid substrate binding, we developed mechanism-based irreversible inhibitors modified with a peptide derived from a natural rhomboid substrate.

To determine allele-specific binding difference, we developed a BAB score using following formula: log2 [test RCvariant/RCreference)/input RCvariant/RCreference)].

Because our goal was to identify DNA methylation-dependent binding activity, we developed a competition assay on a protein microarray to identify TFs that prefer DNA motifs carrying mCpGs.

To obtain the combined properties of both the LysM and PMB domains and also to increase the number of binding partners, we developed a fusion protein by genetic fusion of the three C-terminal LysM motifs of a major autolysin, AcmA from Lactococcus lactis, and three C-terminal PMB motifs of the surface S-layer protein MTH719 from Methanothermobacter thermautotrophicus (see Fig.  1).

Because the C3d region known as p28 represents the complement receptor (CR) 2-binding motif, we developed a CSP-3 copies of p28 DNA construct (CSP-3p28).

Using a newly synthesized gibberellin analog containing an acetoxymethyl group (GA(3 -AM) and its binding proteins, we developed an efficient chemically inducible dimerization (CID) system that is completely orthogonal to existing rapamycin-mediated protein dimerization.

To determine CaRF-specific binding sites, we developed an algorithm to identify the sequences specifically enriched in the ChIP samples from Carf WT neurons relative to the negative control ChIP samples from Carf KO neurons.

To screen for small molecule inhibitors of MSI1 RNA-binding activity, we developed an in vitro assay pipeline amenable to high throughput measurements.

To identify inhibitors of DNA binding to NF-κB, we developed a new homogeneous method for detection of sequence-specific DNA-binding proteins.